conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Participants who have completed 52-week Treatment Period as per protocol in a Novartis study of secukinumab in PMR patients (the "core study" - Study CAIN457C22301), AND * who have experienced a ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Compared with placebo, secukinumab demonstrated superior pain reduction in moderate to severe hidradenitis suppurativa in two phase 3 trials. Improvements in pain were sustained through week 52 ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

"Vasculitis Clinical Trials"Vasculitis companies are R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn, ChemoCentryx, Hoffman-la-Roche ...

Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion acquisition of Chinook Therapeutics, including a former director of the ...

Drugmakers Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis all sued the government after HRSA blocked their plans to pay hospitals rebates to defray the full cost of 340B medications after ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...